CPT® Code 90646

Official Description

Hemophilus influenza b vaccine (Hib), PRP-D conjugate, for booster use only, intramuscular use

Common Language Description

The CPT® Code 90646 refers to the Hemophilus influenza b vaccine (Hib), specifically the PRP-D conjugate formulation, which is designated for booster use only and is administered via intramuscular injection. Vaccines, unlike immune globulins that offer short-term, passive immunity, are designed to provide active, long-term immunity. This is achieved by introducing altered versions of specific pathogens, such as viruses or bacteria, into the recipient's immune system. This exposure prompts the immune system to produce its own antibodies, enabling the body to "remember" how to respond effectively upon future encounters with the same antigen. Hemophilus influenza type b (Hib) is particularly concerning for children under the age of five, as it can lead to severe health complications, including pneumonia, significant swelling of the throat, infections in the joints and bones, and meningitis, which may result in lasting effects such as brain damage and hearing loss. The codes associated with Hib vaccines, including 90646, are used to report the specific conjugate vaccine administered. It is important to note that this code is distinct from others in the Hib vaccine series, such as code 90645, which covers the HbOC conjugate 4-dose schedule, code 90647, which pertains to the PRP-OMP conjugate 3-dose schedule, and code 90648, which indicates the PRP-T conjugate 4-dose schedule. Each of these codes is utilized solely to report the specific vaccine product administered.

1. Indications

The Hemophilus influenza b vaccine (Hib), PRP-D conjugate, is indicated for use as a booster in individuals who have previously received the primary series of Hib vaccinations. This vaccine is specifically recommended for children under the age of five, who are at a higher risk for serious Hib-related diseases. The conditions that warrant the administration of this booster vaccine include:

Booster Requirement The vaccine is administered to enhance and prolong immunity against Hemophilus influenza type b after the initial vaccination series has been completed.
Age Consideration It is particularly indicated for children under five years of age, as they are more susceptible to severe infections caused by Hib.

2. Procedure

The administration of the Hemophilus influenza b vaccine (Hib), PRP-D conjugate, involves several procedural steps to ensure proper delivery and patient safety. The steps are as follows:

Step 1: Patient Assessment Prior to vaccination, the healthcare provider should assess the patient's vaccination history to confirm that the individual is eligible for the booster dose. This includes verifying that the patient has completed the primary series of Hib vaccinations.
Step 2: Preparation of Vaccine The vaccine should be prepared according to the manufacturer's instructions. This includes checking the expiration date, ensuring the vaccine is stored at the correct temperature, and shaking the vial gently to mix the vaccine if necessary.
Step 3: Site Selection The healthcare provider should select an appropriate site for intramuscular injection, typically the anterolateral thigh for infants and young children or the deltoid muscle for older children and adults.
Step 4: Administration of Vaccine The vaccine is administered via intramuscular injection. The provider should use a sterile needle and syringe, and follow standard infection control practices to minimize the risk of infection.
Step 5: Post-Administration Care After the vaccine is administered, the healthcare provider should monitor the patient for any immediate adverse reactions, providing appropriate care if necessary. The patient or guardian should be informed about potential side effects and the importance of follow-up vaccinations.

3. Post-Procedure

Following the administration of the Hemophilus influenza b vaccine (Hib), PRP-D conjugate, patients are typically advised to remain in the healthcare setting for a short period to monitor for any immediate adverse reactions, such as allergic responses. Common side effects may include mild pain or swelling at the injection site, fever, or irritability. Parents or guardians should be educated on these potential reactions and advised to seek medical attention if severe symptoms occur. It is also important to document the administration of the vaccine in the patient's medical record, including the date, site of injection, and any observed reactions. Follow-up appointments should be scheduled as necessary to ensure that the patient remains up to date with their immunization schedule.

Short Descr	HIB VACCINE PRP-D IM
Medium Descr	HEMOPHILUS INFLUENZA B VACCINE PRP-D BOOSTER IM
Long Descr	Hemophilus influenza b vaccine (Hib), PRP-D conjugate, for booster use only, intramuscular use
Status Code	Excluded from Physician Fee Schedule by Regulation
Global Days	XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC)	9 - Not Applicable
Multiple Procedures (51)	9 - Concept does not apply.
Bilateral Surgery (50)	9 - Concept does not apply.
Physician Supervisions	09 - Concept does not apply.
Assistant Surgeon (80, 82)	9 - Concept does not apply.
Co-Surgeons (62)	9 - Concept does not apply.
Team Surgery (66)	9 - Concept does not apply.
Diagnostic Imaging Family	99 - Concept Does Not Apply
APC Status Indicator	Items and Services Packaged into APC Rates
Type of Service (TOS)	1 - Medical Care
Berenson-Eggers TOS (BETOS)	O1G - Immunizations/Vaccinations
MUE	Not applicable/unspecified.
CCS Clinical Classification	228 - Prophylactic vaccinations and inoculations